English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe findings, published in the Journal of the National Cancer Institute, show that markers of cellular aging—such as DNA damage response, cellular senescence, and inflammatory pathways—significantly increased in all breast cancer survivors, regardless of the type of treatment received.
Tag: Cancer Therapies
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics, Inc. , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers, announces that the first U.S. patient has been dosed in the Company’s Phase 3 study to treat metastatic sarcoma (NCT06263231).
MD Anderson and Sibylla Biotech announce strategic collaboration to discover and develop small-molecule protein degraders
The University of Texas MD Anderson Cancer Center and Sibylla Biotech today announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders (FIDs), which disrupt the proper folding of target proteins and lead to their degradation.
Estrogen-negative cancers respond to anti-estrogenic therapies
Anti-estrogenic therapies can suppress the growth of cancer that does not express estrogen receptors; when combined with immune checkpoint inhibitor therapies, they halt tumor progression in mice models.
MD Anderson and Nexo Therapeutics announce strategic research collaboration to advance new therapies against intractable targets
MD Anderson and Nexo announced a strategic research collaboration to rapidly advance new cancer therapies against previously undruggable targets.
Oncology Researcher Joins Rutgers Global Health Institute
Wilfred Ngwa, named a Rutgers Presidential Faculty Scholar and a professor of global health, advises the Biden Administration’s Cancer Cabinet
Rhombic lip implicated in origins of high-risk medulloblastoma
Scientists from St. Jude Children’s Research Hospital found that group 3 and 4 medulloblastoma arise from the rhombic lip, knowledge that may help improve research models and therapeutic development.
Prompt Recognition and Treatment Found Effective for Lung Disease in Patients Who Received New Drug for Advanced Cancer
Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open on August 11, 2022.
Better understanding of DNA repair protein could lead to novel cancer therapies
Summer is here, and that means more time soaking up the sun for many of us.
Focus Fund and MD Anderson launch investment fund to support promising investigational cancer therapies in early-stage clinical trials
The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused investment fund designed to support the advancement of compelling investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials.
UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Boehringer Ingelheim and MD Anderson form unique virtual research and development center to rapidly advance new cancer therapies
Boehringer Ingelheim and MD Anderson have announced a new multi-year partnership to conduct collaborative research, combining the drug-development capabilities of MD Anderson with the pipeline of novel medicines from Boehringer Ingelheim.